{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T08:35:58Z","timestamp":1786523758276,"version":"build-2736575974"},"reference-count":31,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"Korean government","doi-asserted-by":"publisher","award":["RS-2022-NR069528"],"award-info":[{"award-number":["RS-2022-NR069528"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Imdang Scholarship & Cultural Foundation"},{"name":"FutureChem Co., Ltd.","award":["NCT05004285"],"award-info":[{"award-number":["NCT05004285"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background: This study aimed to evaluate the association between the uptake on F-18 florastamin PET\/CT, which targets the prostate-specific membrane antigen (PSMA), and the histopathological grade of the primary tumor in newly diagnosed prostate cancer patients. Methods: As a subset analysis of a phase III multicenter trial of florastamin PET\/CT in East Asian men, the data from a single institution of pathologically confirmed prostate cancer cases were reviewed. The maximum standardized uptake value (SUVmax) was measured from the primary tumor on florastamin PET\/CT images of 110 participants. The International Society of Urological Pathology (ISUP) grade group obtained from surgery or biopsy was classified into three risk groups: low (ISUP 1), intermediate (ISUP 2\u20133), or high (ISUP 4\u20135). Correlation was tested between the SUVmax of the prostate cancer and the ISUP-based risk. The PSA level and Prostate Imaging Reporting and Data System (PIRADS) score from MRI were also assessed for association with the SUVmax and ISUP-based risk. Results: The SUVmax of the primary tumor and the PSA level showed significant positive correlation with the ISUP-based risk (\u03c1 = 0.541, p &lt; 0.001; \u03c1 = 0.328, p = 0.001, respectively). The tumor SUVmax increased with higher PIRADS scores (\u03c1 = 0.516, p &lt; 0.001). Conclusions: The SUVmax of the primary tumor on florastamin PET\/CT was associated with the ISUP-based risk in East Asian men with prostate cancer, suggesting that it could be an imaging biomarker of tumor aggressiveness.<\/jats:p>","DOI":"10.3390\/diagnostics16162536","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T07:57:26Z","timestamp":1786521446000},"page":"2536","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Florastamin Uptake on PSMA PET\/CT as an Imaging Biomarker of Tumor Aggressiveness in Prostate Cancer"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2978-4913","authenticated-orcid":false,"given":"Yeongjoo","family":"Lee","sequence":"first","affiliation":[{"name":"Division of Nuclear Medicine, Department of Radiology, College of Medicine, Seoul St. Mary\u2019s Hospital, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6568-5915","authenticated-orcid":false,"given":"Joo Hyun","family":"O","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine, Department of Radiology, College of Medicine, Seoul St. Mary\u2019s Hospital, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seunggyun","family":"Ha","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine, Department of Radiology, College of Medicine, Seoul St. Mary\u2019s Hospital, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9150-0593","authenticated-orcid":false,"given":"Chansoo","family":"Park","sequence":"additional","affiliation":[{"name":"Research Institute of Labeling, FutureChem Co., Ltd., Seoul 04794, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8496-8825","authenticated-orcid":false,"given":"Dongho","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Urology, College of Medicine, Seoul St. Mary\u2019s Hospital, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9352-3411","authenticated-orcid":false,"given":"Hyong Woo","family":"Moon","sequence":"additional","affiliation":[{"name":"Department of Urology, College of Medicine, Seoul St. Mary\u2019s Hospital, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6775-1157","authenticated-orcid":false,"given":"Ji Youl","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Urology, College of Medicine, Seoul St. Mary\u2019s Hospital, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"ref_1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14740\/wjon1191","article-title":"Epidemiology of Prostate Cancer","volume":"10","author":"Rawla","year":"2019","journal-title":"World J. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.eururo.2012.02.054","article-title":"International variation in prostate cancer incidence and mortality rates","volume":"61","author":"Center","year":"2012","journal-title":"Eur. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Pyun, J.H., Ko, Y.H., Kim, S.W., and Son, N.H. (2024). The Short- and Long-Term Anticipation of Prostate Cancer Incidence in Korea: Based on Social Aging Trends and Prostate-Specific Antigen Testing Rate during the Last Decade. Cancers, 16.","DOI":"10.3390\/cancers16030503"},{"key":"ref_5","first-page":"479","article-title":"Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology","volume":"17","author":"Mohler","year":"2019","journal-title":"J. Natl. Compr. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","article-title":"The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System","volume":"40","author":"Epstein","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.eururo.2012.01.050","article-title":"Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: Incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades","volume":"61","author":"Epstein","year":"2012","journal-title":"Eur. Urol."},{"key":"ref_9","first-page":"247","article-title":"Clinical impact of MRI-based risk calculators for prostate cancer diagnosis: A systematic review and meta-analysis","volume":"29","author":"Boakye","year":"2025","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2967\/jnumed.125.270650","article-title":"Prospective Histopathologic Comparison Between [18F]PSMA-1007 PET\/CT and [18F]Fluciclovine PET\/CT of Intraprostatic Tumor Detection: The TRACER Study","volume":"67","author":"Hoekstra","year":"2026","journal-title":"J. Nucl. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1053\/j.semnuclmed.2024.10.004","article-title":"Update on PSMA-based Prostate Cancer Imaging","volume":"54","author":"Mena","year":"2024","journal-title":"Semin. Nucl. Med."},{"key":"ref_12","first-page":"96","article-title":"Imaging of prostate cancer with PET\/CT using 18F-Fluorocholine","volume":"5","author":"Vali","year":"2015","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"7140","DOI":"10.1002\/cam4.5516","article-title":"Ability of 68Ga-PSMA PET\/CT SUVmax to differentiate ISUP GG2 from GG3 in intermediate-risk prostate cancer: A single-center retrospective study of 147 patients","volume":"12","author":"Yi","year":"2023","journal-title":"Cancer Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.prnil.2025.07.001","article-title":"18F-florastamin positron emission tomography\/computed tomography in men with clinical suspicion of prostate cancer: A phase I prospective study","volume":"13","author":"Park","year":"2025","journal-title":"Prostate Int."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s12149-023-01823-2","article-title":"Multi-timepoint imaging with PSMA-targeted [18F]F-Florastamin PET\/CT: Lesion detection and comparison to conventional imaging","volume":"37","author":"Sheikhbahaei","year":"2023","journal-title":"Ann. Nucl. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00259-020-04883-y","article-title":"A microdose clinical trial to evaluate [18F]Florastamin as a positron emission tomography imaging agent in patients with prostate cancer","volume":"48","author":"Lee","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1097\/PAS.0000000000001497","article-title":"The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma","volume":"44","author":"Grignon","year":"2020","journal-title":"AM J. Surg. Pathol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s13139-025-00946-w","article-title":"Bridging the Gap: PSMA Radioligand Therapy for Asian Men with Prostate Cancer","volume":"59","author":"Suh","year":"2025","journal-title":"Nucl. Med. Mol. Imaging"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.urology.2024.10.026","article-title":"PSMA PET-targeted Biopsy for Prostate Cancer Diagnosis: Initial Experience From a Multicenter Cohort","volume":"196","author":"Checcucci","year":"2025","journal-title":"Urology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00259-020-04863-2","article-title":"68Ga-PSMA PET\/CT targeted biopsy for the diagnosis of clinically significant prostate cancer compared with transrectal ultrasound guided biopsy: A prospective randomized single-centre study","volume":"48","author":"Zhang","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00259-017-3631-6","article-title":"68Ga-PSMA-11 PET\/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour","volume":"44","author":"Uprimny","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.3390\/curroncol31090391","article-title":"The Relationship between D\u2019Amico and ISUP Risk Classifications and 68Ga-PSMA PET\/CT SUVmax Values in Newly Diagnosed Prostate Cancers","volume":"31","author":"Hasbek","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11604-024-01646-9","article-title":"PSMA PET\/CT imaging and its application to prostate cancer treatment","volume":"43","author":"Otani","year":"2025","journal-title":"Jpn. J. Radiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41585-021-00442-8","article-title":"Epidemiology and genomics of prostate cancer in Asian men","volume":"18","author":"Zhu","year":"2021","journal-title":"Nat. Rev. Urol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.7150\/thno.96322","article-title":"Impact of TP53 loss-of-function alterations on the response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients","volume":"14","author":"Slootbeek","year":"2024","journal-title":"Theranostics"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Xu, L., Chen, R., Yu, X., Liu, J., and Wang, Y. (2023). 18F-FDG PET Is Not Inferior to 68Ga-PSMA PET for Detecting Biochemical Recurrent Prostate Cancer with a High Gleason Score: A Head-to-Head Comparison Study. Diagnostics, 14.","DOI":"10.3390\/diagnostics14010007"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1007\/s00259-025-07646-9","article-title":"Dual-tracer PET\/CT identifies an aggressive PSMA-negative\/FDG-positive phenotype predicting early failure of radical prostatectomy in treatment-naive prostate cancer","volume":"53","author":"Chen","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13014-024-02483-w","article-title":"Quantitative PSMA-PET parameters in localized prostate cancer: Prognostic and potential predictive value","volume":"19","author":"Amthauer","year":"2024","journal-title":"Radiat. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1007\/s00259-024-06594-0","article-title":"The accuracy and intra- and interobserver variability of PSMA PET\/CT for the local staging of primary prostate cancer","volume":"51","author":"Donswijk","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1097\/MNM.0000000000001438","article-title":"68Ga-PSMA-I&T-PET\/CT interobserver and intraobserver agreement for prostate cancer: A lesion based and subregional comparison study among observers with different levels of experience","volume":"42","author":"Soyluoglu","year":"2021","journal-title":"Nucl. Med. Commun."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/16\/2536\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T08:11:48Z","timestamp":1786522308000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/16\/2536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":31,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["diagnostics16162536"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics16162536","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]}}}